Skip to main content
. 2022 Aug 3;14:17588359221116604. doi: 10.1177/17588359221116604

Figure 1.

Figure 1.

Partitioned survival model simulating outcomes for the CheckMate 743 trial. The model considers the transition states of unresectable MPM. All patients start in the PFD state and receive treatment with the two treatment plans. Patients can enter the state of PD and subsequently move to the state of the death.

C, pemetrexed plus cisplatin/carboplatin; MPM, malignant pleural mesothelioma; NI, nivolumab plus ipilimumab; PD, progressed disease; PFD, progression-free disease.